Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
93.8M
-
Number of holders
-
78
-
Total 13F shares, excl. options
-
31.4M
-
Shares change
-
+10.8M
-
Total reported value, excl. options
-
$546M
-
Value change
-
+$189M
-
Number of buys
-
67
-
Number of sells
-
-11
-
Price
-
$17.52
Significant Holders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) as of Q2 2020
82 filings reported holding CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") as of Q2 2020.
Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) has 78 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.4M shares
of 93.8M outstanding shares and own 33.54% of the company stock.
Largest 10 shareholders include FMR LLC (4.93M shares), PERCEPTIVE ADVISORS LLC (3.66M shares), ORBIMED ADVISORS LLC (2.75M shares), RA CAPITAL MANAGEMENT, L.P. (2.33M shares), Vivo Capital, LLC (2.32M shares), Versant Venture Management, LLC (2.03M shares), BlackRock Inc. (1.77M shares), 5AM Venture Management, LLC (1.36M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.35M shares), and VANGUARD GROUP INC (1.08M shares).
This table shows the top 78 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.